Diadem

Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer's Disease

Retrieved on: 
Monday, June 13, 2022
Dementia, Research, Government budget balance, Knowledge, Disease, Partnership, Gaps, Environment, Organization, University, MRC, Patient, AD, Technology, Medical Research Council, Adoption, Incidence, Diagnosis, Industry, Population, Medical Research Council (United Kingdom), Pharmaceutical industry, Medical imaging, Alzheimer's disease, Diadem

MILAN, June 13, 2022 /PRNewswire/ -- Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced that is has joined Dementias Platform UK (DPUK) as a corporate partner.

Key Points: 
  • It offers facilitated access to detailed information on more than three million individuals from 50 long-term health cohort studies.
  • "We welcome the opportunity to join this unique network of research institutions and healthcare companies working together to transform the diagnosis and treatment of dementia," said Paul Kinnon, Chief Executive Officer of Diadem.
  • The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer's disease.
  • Diadem is preparing for commercialisation of AlzoSurePredict in collaboration with global strategic partners.

Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Retrieved on: 
Thursday, April 28, 2022
HIV disease progression rates, CEO, Howard Brody, Patient, Amyloid, Research, Incidence, Environmental Modification Convention, Cancer, PTM, Disease, Ageing, Oxidative stress, Diagnosis, Professor, Adoption, Protein, Parkinson's disease, Doctor of Philosophy, Government budget balance, Neurodegeneration, Dementia, University, Genome, Review, Population, Literature, Frontiers Media, Medical device, Medical imaging, Alzheimer's disease, Diadem

MILAN, April 28, 2022 /PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced release of a new peer-reviewed publication, Post-Translational Modifications of the p53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature, in the current issue of the journal Frontiers in Aging Neuroscience. The article reviews the extensive scientific literature that elucidates how post-translational modifications (PTMs) of the protein are associated with the development of Alzheimer's disease. Diadem is leveraging the relationship between p53 conformational variants and AD to develop blood-based prognostic and diagnostic assays for Alzheimer's disease. Its most advanced product, the AlzoSure® Predict assay, is a simple, non-invasive plasma-based biomarker test to accurately predict whether or not a patient with asymptomatic mild cognitive impairment will progress to Alzheimer's dementia up to six years before the disease fully manifests.

Key Points: 
  • The article reviews the extensive scientific literature that elucidates how post-translational modifications (PTMs) of the protein are associated with the development of Alzheimer's disease.
  • Diadem is leveraging the relationship between p53 conformational variants and AD to develop blood-based prognostic and diagnostic assays for Alzheimer's disease.
  • Oxidative stress also has a strong relationship to amyloid and tau-induced neurotoxicity, fueling feedback loops that may accelerate disease progression.
  • A key focus of the review is p53 post-translational modifications, which are seen as the most widespread and effective cellular mechanisms controlling p53 function.

NI Announces New Software Bundle to Help Engineers Optimize Test Systems

Retrieved on: 
Tuesday, March 8, 2022
Manufacturing, Data Management, Technology, Engineering, Software, National Instruments, Investment, Workflow, Software, Research, Industry, Machine learning, Automation, LabVIEW, NATI, Diadem, Multimedia, Technology, Software as a service, NASDAQ, Video game console, TestStand

NI (NASDAQ: NATI) today announced its Test Workflow subscription bundle for automating test systems.

Key Points: 
  • NI (NASDAQ: NATI) today announced its Test Workflow subscription bundle for automating test systems.
  • This offering expands engineers access to the software needed to design and automate a test or measurement system through a single software license.
  • To help them accomplish this goal, NIs new Test Workflow bundle provides streamlined access to several software tools that increase productivity through a SaaS model.
  • Test Workflow ensures engineers have all the software they need to streamline their test and measurement applications and seamlessly transition from design to validation.

FDA Grants Breakthrough Device Designation to Diadem's AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer's Disease

Retrieved on: 
Tuesday, January 18, 2022
Ageing, Patient, Dementia, SAN, University, Incidence, Government budget balance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Probability, Diadem (1800 ship), Adoption, Population, Safety, CEO, AD, Review, Breakthrough, Marketing, Diagnosis, Food, FDA, MedRxiv, Pharmaceutical industry, Medical device, Medical imaging, Alzheimer's disease, Diadem

The FDA Breakthrough Designation is granted to novel medical devices that have the potential to provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.

Key Points: 
  • The FDA Breakthrough Designation is granted to novel medical devices that have the potential to provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.
  • "Obtaining this FDA Breakthrough Device designation reinforces our view that AlzoSure Predict is a potential game changer for the early identification and management of Alzheimer's disease, which afflicts millions of patients and their families worldwide," said Paul Kinnon, CEO of Diadem.
  • The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer's disease.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

Slinger Expands Distribution in Latin America

Retrieved on: 
Monday, December 6, 2021
Slinger, Private Securities Litigation Reform Act, Security (finance), U.S.–Canada Team Tournament (go), Securities Act of 1933, School, Industry, Software as a service, Annual report, Company, Australian Open, UK, Tennis, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Nature, US, Gamma, Risk, PR, GLOBE, Prince, OTCQB, Uncertainty, Dunlop, Uproar, Diadem, Sports equipment, Private investigator, Public relations

BALTIMORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Slinger® (OTCQB: SLBG), a leading connected sports technology company, today announced its newest distribution agreement, with BrandsInc in Ecuador. BrandsInc was established in 2014 with the mission to bring a better experience to sports fans and consumers in the country looking to buy products from top global brands. They possess a strong understanding of the Ecuadorian sports and tennis market and have helped to grow popular tennis brands in the country, including Dunlop, Yonex, Gamma and Diadem.

Key Points: 
  • We are thrilled to be able to represent Slinger in our home country of Ecuador, said BrandsInc CEO Bruce G Valle.
  • We are thrilled to find such great partners in Ecuador and expand our agreements throughout Latin America in recent months, said Slinger CEO Mike Ballardie.
  • The Slinger Bag is available to order now - to find out more about Slinger Bag, visit https://slingerbag.com .
  • Slinger has underpinned its proof of concept with over $250M of retail value in global distribution agreements since the Spring of 2020 for the Slinger Bag.

Diadem Presents Data at 22nd International Conference on Alzheimer's Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging

Retrieved on: 
Wednesday, October 6, 2021
MedRxiv, Dementia, Drug discovery, PET, Diadem, Diagnosis, Alzheimer's Drug Discovery Foundation, Conference, Patient, AUC, Biomarker, AD, MCI, Government budget balance, New product development, International Conference on Information Systems Security and Privacy, Doctor of Philosophy, Medical imaging

The new study results were presented at the 22nd International Conference on Alzheimer's Drug Discovery .

Key Points: 
  • The new study results were presented at the 22nd International Conference on Alzheimer's Drug Discovery .
  • The data was presented on October 5, 2021, at the Alzheimer's Drug Discovery Foundation's 2021 International Conference on Alzheimer's Drug Discovery by Simona Piccirella, PhD, Diadem's Vice President of Product Development and Operations.
  • This new data further confirms the accuracy of AlzoSure, showing that it is highly concordant with amyloid brain imaging, the current gold standard for diagnosing AD.
  • AlzoSure Predict also demonstrated superior predictive performance to PET brain imaging measures of amyloid bload (P

Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA

Retrieved on: 
Tuesday, September 14, 2021
Cancer, Biology, Biotechnology, Ecosystem, Genetic engineering, Inflammation, Creative Biolabs, Patient, Lundquist, Genetics, Disease, Industry, Therapy, NASDAQ, Solution, TLI, AMGN, Growth, Benaroya Research Institute, Degenerative disease, Charles A. Lundquist, Exosome, Partnership, Diadem, Golden Ticket, Research, Film, Pharmaceutical industry, Fine chemical

Diadem will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.

Key Points: 
  • Diadem will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.
  • The 2021 Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders at a virtual pitch event.
  • "Amgen's partnership with BioLabs LA at The Lundquist Institute (TLI) recognizes the rapid growth of bioscience innovation in the Los Angeles area and aligns with our aspiration to bring breakthrough therapies for patients.
  • We look forward to having Diadem join the BioLabs LA community and in assisting them, along with Amgen and The Lundquist Institute, in reaching their milestones.